Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
November 04 2020 - 4:05PM
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the
“Company”), a clinical-stage dermatology company focused on
identifying, developing and commercializing branded and generic
topical drug products for the treatment of skin diseases, will
report third quarter 2020 financial results on Thursday, November
12, 2020 at 7:05 AM ET.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on
identifying, developing and commercializing branded and generic
topical drug products for the treatment of skin
diseases. Sol-Gel leverages its proprietary
microencapsulation technology platform for the development of
Twyneo, under investigation for the treatment of acne vulgaris, and
Epsolay, under investigation for the treatment of papulopustular
rosacea. The Company’s pipeline also includes SGT-210, an
early-stage topical epidermal growth factor receptor inhibitor,
erlotinib, under investigation for the treatment
of palmoplantar keratoderma, and preclinical assets tapinarof
and roflumilast. For additional information, please
visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:Gilad MamlokChief Financial
Officer+972-8-9313433
Investor Contact:Lee M. SternSolebury
Trout+1-646-378-2922lstern@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From Sep 2023 to Sep 2024